Solventum Corp. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Solventum Corporation, a global healthcare company spun off from 3M in April 2024, operates through three reportable segments: MedSurg, Dental Solutions, and Health Information Systems. The company is a large accelerated filer with common stock trading on the NYSE under the symbol "SOLV."
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Net Sales | $2,007 million | $2,070 million |
| Operating Income | $81 million | $152 million |
| Net Income | $13 million | $137 million |
| Diluted EPS | $0.07 | $0.78 |
| Operating Cash Flow | ($189 million) used | $29 million provided |
| Cash and Equivalents | $561 million | $534 million |
| Total Debt (Carrying Value) | $5,080 million | $5,035 million |
| Interest Expense, Net | $62 million | $104 million |
Material Changes vs. Prior Period
- Revenue Decline: Total net sales decreased 3.0% year-over-year, driven by a 7.8% negative impact from the divestiture of the Purification and Filtration business in September 2025. Organic growth was positive at 2.1%.
- Profitability Compression: Operating income fell 46.7% to $81 million. This was primarily due to higher product costs (tariffs and inflation), increased SG&A expenses related to separation activities, and restructuring charges of $37 million under the "Transform for the Future" program.
- Net Income Volatility: Net income dropped significantly from $137 million to $13 million. The prior year included a non-recurring tax benefit of $99 million related to the Purification and Filtration divestiture, which was absent in Q1 2026.
- Cash Flow Shift: Operating cash flow turned negative ($189 million used) compared to positive flow in the prior year, largely due to higher payments for annual incentive compensation and exit costs from transition agreements with 3M.
- Debt Reduction: Interest expense decreased 40% due to lower debt outstanding, despite a slight increase in total carrying value due to new borrowings and lease liabilities.
Outlook, Risks, and Management Commentary
- Restructuring: The "Transform for the Future" initiative is expected to generate approximately $500 million in annual cost savings over four years, with cumulative pretax costs of roughly $500 million.
- Tariff Uncertainty: Management notes uncertainty regarding potential refunds of tariffs previously paid under the IEEPA following a March 2026 court ruling. No benefit has been recorded as of March 31, 2026.
- Legal Contingencies: The company faces significant litigation regarding the Bair Hugger patient warming system, for which it indemnifies 3M. Accrued litigation costs were $31 million as of March 31, 2026.
- Share Repurchases: The company repurchased 922,636 shares for $67 million under a $1 billion program approved in November 2025.
- Segment Performance: MedSurg operating income declined 21.8% due to cost pressures, while Dental Solutions and Health Information Systems saw operating income increases of 10.8% and 19.9%, respectively.
Investor Verification Checklist
- Tariff Refund Status: Verify the administrative process and likelihood of recovering IEEPA tariffs paid in 2025 following the March 2026 court ruling.
- Restructuring Execution: Monitor the pace of cost savings realization versus the $500 million cumulative cost target for the "Transform for the Future" program.
- Legal Exposure: Track developments in the Bair Hugger multidistrict litigation (MDL) and potential impacts on indemnification obligations to 3M.
- Working Capital Trends: Assess the sustainability of negative operating cash flow, specifically regarding the timing of incentive compensation payments and transition service agreement exits.
- Segment Margins: Evaluate whether MedSurg can offset tariff-driven cost increases through pricing or efficiency gains to restore historical operating margins.